Piergiorgio Donati
Directeur Technique/Scientifique/R&D chez AC IMMUNE SA
Fortune : 56 153 $ au 30/04/2024
Provenance du réseau au premier degré de Piergiorgio Donati
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
31
| Public Company | Pharmaceuticals: Major | 31 |
Glenmark Pharmaceuticals Inc., USA
 Glenmark Pharmaceuticals Inc., USA Pharmaceuticals: MajorHealth Technology Glenmark Pharmaceuticals USA, Inc. manufactures, markets, and distributes generic pharmaceutical products. It offers campral delayed-release tablets, differin gel, aclovate cream, aclovate topical ointment, ortho novum, and other related products. The company was founded in 2003 and is headquartered in Mahwah, NJ.
1
| Subsidiary | Pharmaceuticals: Major | 1 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Piergiorgio Donati via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
| dievini Verwaltungs GmbH | Chief Executive Officer Chief Executive Officer Chief Executive Officer | ||
Molecular Health GmbH
 Molecular Health GmbH Miscellaneous Commercial ServicesCommercial Services Part of Posbelduf Biotech AG, Molecular Health GmbH is a German management consulting company. The company is based in Heidelberg, Germany. The company was founded in 2004 by Friedrich von Bohlen und Halbach. Friedrich von Bohlen und Halbach has been the CEO since 2004. | Miscellaneous Commercial Services | Chief Executive Officer Chairman Director/Board Member | |
| 2INVEST AG | Financial Conglomerates | Director/Board Member Director/Board Member Director/Board Member | |
dievini Hopp BioTech holding GmbH & Co. KG
 dievini Hopp BioTech holding GmbH & Co. KG Investment ManagersFinance dievini Hopp BioTech holding GmbH & Co. KG operates as a private investment and consulting firm. It invests in companies related to the life and health sciences. It focuses with companies that diagnoses and provides therapy in the fields of oncology, neurology, infectious diseases, cell therapy and drug delivery systems. The company is headquartered in Walldorf, Germany. | Investment Managers | Private Equity Investor Founder Chief Executive Officer | |
| University of Lausanne | College/University | Corporate Officer/Principal Corporate Officer/Principal Doctorate Degree | |
| HEIDELBERG PHARMA AG | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member | |
| IMMATICS N.V. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
CureVac SE
 CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
Molecular Health, Inc.
 Molecular Health, Inc. Packaged SoftwareTechnology Services Molecular Health, Inc. operates as a cloud-based healthcare decision support technology to enable evidence-based treatment decisions. The company was founded in 2004 and is headquartered in Boston, MA. | Packaged Software | Chairman Director/Board Member Director/Board Member | |
Immatics Biotechnologies GmbH
 Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Novaliq GmbH
 Novaliq GmbH Medical SpecialtiesHealth Technology Novaliq GmbH develops and markets drug delivery systems. The firm specializes in the development of novel pharmaceutical formulations based on semifluorinated alkanes . It product pipeline encompasses the NovaTears, CyckAol, and I-Let Protect technologies. The company was founded in 2004 and is headquartered in Heidelberg, Germany. | Medical Specialties | Chairman Director/Board Member | |
| Febit, Inc. | Director/Board Member Chairman | ||
febit holding GmbH
 febit holding GmbH Medical/Nursing ServicesHealth Services febit holding GmbH engages in the design and development of technologies used for DNA analysis. It specializes in technologies with applications in genomic research, RNA expression profiling, and other diagnostic and molecular biology fields. The company was founded by Markus Beier, Ramon Gueimil, Peer F. Staehler, Matthias Scheffler, and Cord F. Stähler in 2005 and is headquartered in Heidelberg, Germany. | Medical/Nursing Services | Director/Board Member Chairman | |
Immatics US, Inc.
 Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX. | Biotechnology | Director/Board Member Director/Board Member | |
| Swiss Federal Institute of Technology | College/University | Doctorate Degree Doctorate Degree | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| CUREVAC N.V. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Inventages II
 Inventages II Investment ManagersFinance Inventages II invests in companies located in Bahamas. The fund focus on companies such as life science and consumer applications. It provides financing for seed, early and buyout capital requirements. | Investment Managers | Founder Founder | |
Apogenix AG
 Apogenix AG BiotechnologyHealth Technology Apogenix AG develops immuno-oncology therapeutics for the treatment of cancer and malignant diseases. It offers protein-based therapeutics, including APG101, a human soluble fusion protein combining the extracellular domain of the CD95-receptor and the Fc part blocking CD95L-mediated signaling pathways; and IL-4 blocker that prevents over expression of anti-apoptotic proteins cells. The firm offers its drugs for malignant and inflammatory diseases. The company was founded by Peter Heinrich Krammer and Henning Walczak in 2005 and is headquartered in Heidelberg, Germany. | Biotechnology | Chairman Director/Board Member | |
| AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| École Polytechnique Fédérale de Lausanne | College/University | Graduate Degree Doctorate Degree | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Corporate Officer/Principal Graduate Degree | |
| IRONWOOD PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Director of Finance/CFO | |
| Suva City Council | Corporate Officer/Principal | ||
| Technical University of Berlin | College/University | Graduate Degree | |
Amal Therapeutics SA
 Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | Biotechnology | Founder | |
| World Demographic & Ageing Forum | Corporate Officer/Principal | ||
| Institute of Public Finance & Fiscal Law | Corporate Officer/Principal | ||
| Schweizerische Management Gesellschaft | Director/Board Member | ||
| SWISS LIFE HOLDING AG | Life/Health Insurance | Director/Board Member | |
| SCHINDLER HOLDING AG | Industrial Machinery | Director/Board Member | |
HUBER+SUHNER (UK) Ltd.
 HUBER+SUHNER (UK) Ltd. Electronic Production EquipmentElectronic Technology HUBER+SUHNER (UK) Ltd. manufactures, imports, and sells electrical and optical connectivity components and accessories. It offers radio frequency and fiber optic products including antennas, assemblies, cables, connectors and adapters, lightning and EMP protectors, and resistive components. The company was founded on March 30, 1967 and is headquartered in Bicester, the United Kingdom. | Electronic Production Equipment | Director/Board Member | |
| Swiss Federal Commission for Economic Issues | Corporate Officer/Principal | ||
| Gebert Rüf Stiftung | Corporate Officer/Principal | ||
| University of Tilburg | College/University | Corporate Officer/Principal | |
| Richard Büchner Foundation | Director/Board Member | ||
| Swiss Society of Economics & Statistics | President | ||
| Swiss Institute For Intl Economics & Applied Economic Research | Chairman | ||
| Center for Disability & Integration | Corporate Officer/Principal | ||
| HUBER+SUHNER AG | Telecommunications Equipment | Director/Board Member | |
| CESifo Research Network | Corporate Officer/Principal | ||
| Network for Studies on Pensions Aging Retirement | Corporate Officer/Principal | ||
| SCHWEIZERISCHE NATIONALBANK | Major Banks | Director/Board Member | |
| Max Schmidheiny-Stiftung | Investment Trusts/Mutual Funds | Corporate Officer/Principal |
Statistiques
Internationale
| Suisse | 20 |
| Allemagne | 19 |
| Etats-Unis | 9 |
| Pays-Bas | 3 |
| Fidji | 2 |
Sectorielle
| Health Technology | 16 |
| Consumer Services | 7 |
| Finance | 6 |
| Commercial Services | 4 |
| Electronic Technology | 3 |
Opérationnelle
| Director/Board Member | 134 |
| Corporate Officer/Principal | 56 |
| Chairman | 44 |
| Chief Executive Officer | 31 |
| Independent Dir/Board Member | 27 |
Relations les plus connectées
| Insiders | |
|---|---|
| Christof Hettich | 40 |
| Friedrich von Bohlen und Halbach | 36 |
| Alan Colowick | 30 |
| Douglas Williams | 25 |
| Monika Bütler | 25 |
| Mathias Hothum | 19 |
| Martin Velasco | 15 |
| Werner Lanthaler | 13 |
| Thomas Graney | 11 |
| Andrea Pfeifer | 11 |
| Carl June | 9 |
| Fred Grossman | 9 |
| Gary Waanders | 8 |
| Monica Shaw | 8 |
| Sonia Maria Poli | 7 |
- Bourse
- Insiders
- Piergiorgio Donati
- Connexions Sociétés
